Comparative Pharmacology
Head-to-head clinical analysis: MEDIHALER ERGOTAMINE versus WIGRAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEDIHALER ERGOTAMINE versus WIGRAINE.
MEDIHALER ERGOTAMINE vs WIGRAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergotamine is a serotonin (5-HT1B/1D) receptor agonist with additional affinity for 5-HT2, dopamine D2, and alpha-adrenergic receptors. It causes vasoconstriction of cranial blood vessels and inhibits neurogenic inflammation.
WIGRAINE is a combination product containing ergotamine, a vasoconstrictor that acts as an agonist at serotonin (5-HT1B/1D) and alpha-adrenergic receptors, and caffeine, which enhances ergotamine absorption and provides additional vasoconstriction.
One inhalation (0.36 mg ergotamine) at onset of migraine; may repeat after 5 minutes if needed, up to 6 inhalations per attack and 15 per week.
For acute migraine: 2 tablets (each containing ergotamine tartrate 1 mg and caffeine 100 mg) orally at onset, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack, maximum 10 tablets per week.
None Documented
None Documented
The terminal elimination half-life is approximately 2 hours for the initial phase, followed by a prolonged terminal phase of 21-30 hours due to slow release from tissue binding sites. This long terminal half-life contributes to the risk of accumulation and toxicity with frequent dosing.
Ergotamine: ~2-3 hours (terminal). Clinical context: short half-life necessitates frequent dosing for acute migraine relief.
Ergotamine is extensively metabolized in the liver. Approximately 90% of the dose is excreted as metabolites in the bile/feces, with less than 3% excreted unchanged in urine.
Primarily hepatic metabolism; renal excretion of metabolites. ~90% urinary, ~10% fecal.
Category D/X
Category C
Ergot Alkaloid
Ergot Alkaloid